Meet Fortrea at ESMO Congress 2025
Fortrea is excited to participate in the European Society for Medical Oncology (ESMO) Congress 2025, a premier global event that brings together oncology professionals, researchers, and innovators from around the world.
Join us at Booth 3032 to explore how Fortrea is helping reshape the future of oncology through powerful clinical development strategies, deep therapeutic specialists, and patient-focused solutions. Whether you're advancing early-phase research or driving late-stage trials, our team is here to collaborate and support your goals.
Connect with our specialists at ESMO 2025 to discuss your pipeline, explore partnership opportunities, and discover how we’re accelerating progress in cancer care—together.
Our oncology specialists will be available to discuss solutions across high-impact domains:
- Tumour-specific development (e.g., breast, lung, hematologic cancers)
- Precision oncology & biomarker strategy
- Complex trial designs (basket, umbrella, platform trials)
- Advanced therapies (cell, gene, immuno-oncology)
- Paediatric and rare oncology trials
- DCT/hybrid trial enablement
- Global patient access & site feasibility
- Long-term survival follow-up & retention planning
Discover Our Oncology Capabilities : https://www.fortrea.com/therapeutics/oncology
See how Fortrea is driving innovation across oncology trials.
Interested in a 1:1 meeting with our experts?
Fill out the Contact Us form at the bottom of the page to schedule a personalized discussion.
Senior Leadership team
Medical team
Strategic Delivery & Growth team
Delivery team
Consulting team
Medical Device & Diagnostics team
Featured Presentation
Title: Capivasertib plus fulvestrant as first- and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the Phase 3 CAPItello-291 trial
Authors | Affiliation |
Hope S Rugo | City of Hope Comprehensive Cancer Center, Duarte, California, USA |
Sibylle Loibl | GBG Forschungs GmbH, Neu-Isenburg, Germany Goethe University, Frankfurt, Germany |
Mafalda Oliveira | Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
Sacha J Howell | The Christie NHS Foundation Trust, Manchester, UK |
Florence Dalenc | Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Toulouse, France |
Javier Cortés | International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain Medica Scientia Innovation Research (MEDSIR), Ridgewood (New Jersey, USA), Barcelona (Spain) |
Henry L Gomez | Instituto Nacional de Enfermedades Neoplásicas (INEN), Departamento de Oncología Médica, Lima, Peru Universidad Ricardo Palma, Lima, Peru |
Xichun Hu | Shanghai Cancer Center, Fudan University, Shanghai, China |
Komal Jhaveri | Memorial Sloan Kettering Cancer Center, New York, New York, USA Institut de Recerca Biomèdica, Barcelona, SpainWeill Cornell Medical College, New York, New York, USA |
Serafin Morales Murillo | Institut de Recerca Biomèdica, Barcelona, Spain |
Zbigniew Nowecki | The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland |
Meena Okera | ICON Cancer Centre, Adelaide, South Australia, Australia |
Yeon Hee Park | Samsung Medical Center, Sungkunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea |
Masakazu Toi | Affiliation at the time the work was conducted: Kyoto University Hospital, Kyoto, Japan |
Lyudmila Zhukova | Loginov Moscow Clinical Scientific Center, Moscow, Russia |
Kamal S Saini | Fortrea Inc., Durham, North Carolina, USA |
Ian Wadsworth | Oncology R&D, AstraZeneca, Cambridge, UK |
Marta Fulford | Oncology R&D, AstraZeneca, Warsaw, Poland |
Vijay Prasad | Oncology R&D, AstraZeneca, Cambridge, UK |
Nicholas C Turner | Royal Marsden Hospital, Institute of Cancer Research, London, UK |